Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Last trade$19.60
Day change-$0.27 (-1.36%)
Day range$19.38 – $20.07
Volume253,037
Market cap$691M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$691.24M
Price / earnings
103.88×
Price / book
5.18×
Price / sales
6.29×
EV / sales
5.78×
EV / EBITDA
103.57×
Profitability
Earnings per share
$0.19
Return on assets
4.46%
Return on equity
4.98%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
10.87×
Quick ratio
10.06×
Cash ratio
4.26×
Cash flow
Price / cash flow
30.06×
Price / free cash flow
34.37×
Free cash flow
$20.11M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DCTH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$35.1M
$29.13M
$24.99M
$20.73M
$20.56M
$24.16M
$19.78M
$15.1M
Cost of revenue
$3.92M
$2.99M
$3.74M
$3.01M
$2.62M
$3.32M
$2.85M
$2.13M
Gross profit
$31.18M
$26.15M
$21.26M
$17.72M
$17.94M
$20.84M
$16.94M
$12.97M
Selling, general and administrative
$13.06M
$13.37M
$13.07M
$10.53M
$10.34M
$11.37M
$11.29M
$7.02M
Research and development
$11.01M
$10.38M
$9.82M
$9.37M
$7.99M
$6.88M
$5.01M
$2.91M
Total operating expenses
$24.07M
$23.75M
$22.9M
$19.9M
$18.33M
$18.25M
$16.3M
$9.94M
Operating income
$7.12M
$2.4M
-$1.64M
-$2.18M
-$388K
$2.59M
$642K
$3.04M
Interest expense
$0
$781K
$787K
$0
$0
$649K
$618K
$0
Income before taxes
$7.97M
$3.16M
-$908K
-$1.33M
$375K
$3.21M
$1.26M
-$3.4M
Income taxes
$1.02M
$491K
$162K
$562K
-$455K
$508K
$195K
$0
Net income
$6.95M
$2.67M
-$1.07M
-$1.9M
$830K
$2.7M
$1.07M
-$3.4M
Net income attributable to common shareholders
$6.95M
$2.67M
-$1.07M
-$1.9M
$830K
$2.7M
$1.07M
-$3.4M
EBITDA
$7.27M
$2.51M
-$1.54M
-$2.1M
-$324K
$2.64M
$685K
$3.08M
Basic earnings per share
$0.19
$0.07
-$0.03
-$0.05
$0.02
$0.08
$0.03
-$0.11
Diluted earnings per share
$0.17
$0.07
-$0.03
-$0.05
$0.02
$0.07
$0.03
-$0.12
Recent news
Company coverage with links to the original publishers.
Delcath Systems (DCTH) has gained 27.6% over 12 weeks and 44.4% over the past four weeks, trading at 92.2% of its 52-week high. The stock carries a Zacks Rank #1 (Strong Buy) rating with an Average Broker Recommendation of #1, indicating strong fundamental strength and potential for continued upward momentum.
Delcath Systems (DCTH) has been identified as a strong momentum stock with a Zacks Rank #1 (Strong Buy) rating and Momentum Style Score of A. The stock has shown impressive performance with a 47.89% monthly gain and 153.43% yearly gain, significantly outperforming the S&P 500. Recent earnings estimate revisions have moved upward, with consensus estimates improving from -$0.17 to $0.13 in the past 60 days.
Delcath Systems (DCTH) has a mean analyst price target of $27.8, suggesting 27.7% upside potential from its current $21.77 price. The stock has gained 47.9% over the past four weeks. Analysts have revised earnings estimates higher, and DCTH holds a Zacks Rank #1 (Strong Buy) rating. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions.
CryoPort, Inc. (CYRX) has returned 81.3% year-to-date, significantly outperforming the Medical sector's 1.6% average return. The company holds a Zacks Rank #2 (Buy) with improving earnings outlook. Delcath Systems, Inc. (DCTH) has also outperformed with a 58.1% year-to-date return and a Zacks Rank #1 (Strong Buy), supported by an 80.7% increase in consensus EPS estimates over three months.
Delcath Systems (DCTH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.